200 related articles for article (PubMed ID: 26967152)
1. Total Synthesis of Laspartomycin C and Characterization of Its Antibacterial Mechanism of Action.
Kleijn LH; Oppedijk SF; 't Hart P; van Harten RM; Martin-Visscher LA; Kemmink J; Breukink E; Martin NI
J Med Chem; 2016 Apr; 59(7):3569-74. PubMed ID: 26967152
[TBL] [Abstract][Full Text] [Related]
2. Semisynthetic approaches to laspartomycin analogues.
Curran WV; Leese RA; Jarolmen H; Borders DB; Dugourd D; Chen Y; Cameron DR
J Nat Prod; 2007 Mar; 70(3):447-50. PubMed ID: 17323996
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of octapeptin C4 and biological profiling against NDM-1 and polymyxin-resistant bacteria.
Becker B; Butler MS; Hansford KA; Gallardo-Godoy A; Elliott AG; Huang JX; Edwards DJ; Blaskovich MAT; Cooper MA
Bioorg Med Chem Lett; 2017 Jun; 27(11):2407-2409. PubMed ID: 28454673
[TBL] [Abstract][Full Text] [Related]
4. Semisynthetic Lipopeptides Derived from Nisin Display Antibacterial Activity and Lipid II Binding on Par with That of the Parent Compound.
Koopmans T; Wood TM; 't Hart P; Kleijn LH; Hendrickx AP; Willems RJ; Breukink E; Martin NI
J Am Chem Soc; 2015 Jul; 137(29):9382-9. PubMed ID: 26122963
[TBL] [Abstract][Full Text] [Related]
5. The structural diversity of acidic lipopeptide antibiotics.
Strieker M; Marahiel MA
Chembiochem; 2009 Mar; 10(4):607-16. PubMed ID: 19156787
[TBL] [Abstract][Full Text] [Related]
6. Design and Solution-Phase Synthesis of Membrane-Targeting Lipopeptides with Selective Antibacterial Activity.
Konai MM; Adhikary U; Haldar J
Chemistry; 2017 Sep; 23(52):12853-12860. PubMed ID: 28718982
[TBL] [Abstract][Full Text] [Related]
7. Structural Insights into the Mode of Action of the Peptide Antibiotic Copsin.
Franzoi M; van Heuvel Y; Thomann S; Schürch N; Kallio PT; Venier P; Essig A
Biochemistry; 2017 Sep; 56(37):4992-5001. PubMed ID: 28825809
[TBL] [Abstract][Full Text] [Related]
8. Targeting bactoprenol-coupled cell envelope precursors.
Ulm H; Schneider T
Appl Microbiol Biotechnol; 2016 Sep; 100(18):7815-25. PubMed ID: 27495122
[TBL] [Abstract][Full Text] [Related]
9. Dissecting the Binding Interactions of Teixobactin with the Bacterial Cell-Wall Precursor Lipid II.
Chiorean S; Antwi I; Carney DW; Kotsogianni I; Giltrap AM; Alexander FM; Cochrane SA; Payne RJ; Martin NI; Henninot A; Vederas JC
Chembiochem; 2020 Mar; 21(6):789-792. PubMed ID: 31552694
[TBL] [Abstract][Full Text] [Related]
10. Laspartomycin, an acidic lipopeptide antibiotic with a unique peptide core.
Borders DB; Leese RA; Jarolmen H; Francis ND; Fantini AA; Falla T; Fiddes JC; Aumelas A
J Nat Prod; 2007 Mar; 70(3):443-6. PubMed ID: 17315928
[TBL] [Abstract][Full Text] [Related]
11. New Found Hope for Antibiotic Discovery: Lipid II Inhibitors.
Ng V; Chan WC
Chemistry; 2016 Aug; 22(36):12606-16. PubMed ID: 27388768
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel cyclic lipopeptides from a positional scanning combinatorial library with enhanced antibacterial and antibiofilm activities.
Bionda N; Fleeman RM; de la Fuente-Núñez C; Rodriguez MC; Reffuveille F; Shaw LN; Pastar I; Davis SC; Hancock REW; Cudic P
Eur J Med Chem; 2016 Jan; 108():354-363. PubMed ID: 26703794
[TBL] [Abstract][Full Text] [Related]
13. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
Lunde CS; Hartouni SR; Janc JW; Mammen M; Humphrey PP; Benton BM
Antimicrob Agents Chemother; 2009 Aug; 53(8):3375-83. PubMed ID: 19470513
[TBL] [Abstract][Full Text] [Related]
14. Initial efforts toward the optimization of arylomycins for antibiotic activity.
Roberts TC; Schallenberger MA; Liu J; Smith PA; Romesberg FE
J Med Chem; 2011 Jul; 54(14):4954-63. PubMed ID: 21630667
[TBL] [Abstract][Full Text] [Related]
15. A High-Resolution Crystal Structure that Reveals Molecular Details of Target Recognition by the Calcium-Dependent Lipopeptide Antibiotic Laspartomycin C.
Kleijn LHJ; Vlieg HC; Wood TM; Sastre Toraño J; Janssen BJC; Martin NI
Angew Chem Int Ed Engl; 2017 Dec; 56(52):16546-16549. PubMed ID: 29108098
[TBL] [Abstract][Full Text] [Related]
16. The contribution of achiral residues in the laspartomycin family of calcium-dependent lipopeptide antibiotics.
Wood TM; Bertheussen K; Martin NI
Org Biomol Chem; 2020 Jan; 18(3):514-517. PubMed ID: 31854417
[TBL] [Abstract][Full Text] [Related]
17. Katanosin B and plusbacin A(3), inhibitors of peptidoglycan synthesis in methicillin-resistant Staphylococcus aureus.
Maki H; Miura K; Yamano Y
Antimicrob Agents Chemother; 2001 Jun; 45(6):1823-7. PubMed ID: 11353632
[TBL] [Abstract][Full Text] [Related]
18. The mode of action of the lantibiotic lacticin 3147--a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II.
Wiedemann I; Böttiger T; Bonelli RR; Wiese A; Hagge SO; Gutsmann T; Seydel U; Deegan L; Hill C; Ross P; Sahl HG
Mol Microbiol; 2006 Jul; 61(2):285-96. PubMed ID: 16771847
[TBL] [Abstract][Full Text] [Related]
19. Insight into invertebrate defensin mechanism of action: oyster defensins inhibit peptidoglycan biosynthesis by binding to lipid II.
Schmitt P; Wilmes M; Pugnière M; Aumelas A; Bachère E; Sahl HG; Schneider T; Destoumieux-Garzón D
J Biol Chem; 2010 Sep; 285(38):29208-16. PubMed ID: 20605792
[TBL] [Abstract][Full Text] [Related]
20. Rational design of new cyclic analogues of the antimicrobial lipopeptide tridecaptin A
Ballantine RD; Li YX; Qian PY; Cochrane SA
Chem Commun (Camb); 2018 Sep; 54(75):10634-10637. PubMed ID: 30179243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
